Becton Dickinson (BDX) Cash from Financing Activities (2009 - 2026)
Becton Dickinson (BDX) reported Cash from Financing Activities of -$414.0 million for Q1 2026, down 989.47% year-over-year from $46.5 million in Q1 2025, and down 37.09% quarter-over-quarter from -$302.0 million in Q4 2025.
Becton Dickinson (BDX) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Becton Dickinson (BDX) has 18 years of Cash from Financing Activities data on file, last reported at -$414.0 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$414.0 million, down 989.47% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.4 billion (down 227.84% YoY), and the FY2025 annual result was -$3.6 billion, down 273.31% from the prior year.
- Cash from Financing Activities declined to -$414.0 million in Q1 2026 per BDX's latest filing, from -$302.0 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $1.7 billion in Q1 2024 and troughed at -$1.9 billion in Q4 2024.
- A 5-year average of -$271.2 million and a median of -$534.0 million in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities soared 427.57% in 2022, then plunged 989.47% in 2026.
- A 5-year view of Cash from Financing Activities shows it stood at -$534.0 million in 2022, then sank by 61.42% to -$862.0 million in 2023, then tumbled by 123.67% to -$1.9 billion in 2024, then soared by 84.34% to -$302.0 million in 2025, then slumped by 37.09% to -$414.0 million in 2026.
- Business Quant data shows BDX's Cash from Financing Activities at -$414.0 million in Q1 2026, -$302.0 million in Q4 2025, and -$809.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | -1.35 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -414.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | -13.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | -255.24 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | -308.70 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | -50.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -75.80 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | -48.13 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | -11.00 Mn |
| 10 | Aptargroup | 7.72 Bn | 7.52 Bn | 351.91 Mn | -230.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -414.00 Mn |
| Mar 31, 2026 | -414.00 Mn |
| Dec 31, 2025 | -302.00 Mn |
| Dec 31, 2025 | -302.00 Mn |
| Sep 30, 2025 | -809.00 Mn |
| Sep 30, 2025 | -809.00 Mn |
| Jun 30, 2025 | -842.00 Mn |
| Jun 30, 2025 | -842.00 Mn |
| Mar 31, 2025 | -38.00 Mn |
| Mar 31, 2025 | -38.00 Mn |
| Dec 31, 2024 | -1.93 Bn |
| Dec 31, 2024 | -1.93 Bn |
| Sep 30, 2024 | 124.00 Mn |
| Sep 30, 2024 | 124.00 Mn |
| Jun 30, 2024 | 1.12 Bn |
| Jun 30, 2024 | 1.12 Bn |
| Mar 31, 2024 | 1.71 Bn |
| Mar 31, 2024 | 1.71 Bn |
| Dec 31, 2023 | -862.00 Mn |
| Dec 31, 2023 | -862.00 Mn |